Lau T, Ma H, Poon R
Life Sci Alliance. 2024; 7(10).
PMID: 39074902
PMC: 11287020.
DOI: 10.26508/lsa.202402670.
Liu H, Zhang H, Han Y, Hu Y, Geng Z, Su J
Theranostics. 2022; 12(15):6576-6594.
PMID: 36185613
PMC: 9516228.
DOI: 10.7150/thno.78034.
Strybol P, Larmuseau M, de Schaetzen van Brienen L, Van den Bulcke T, Marchal K
Cell Rep Methods. 2022; 2(2):100171.
PMID: 35474966
PMC: 9017186.
DOI: 10.1016/j.crmeth.2022.100171.
Xie Y, Li L
Int J Mol Sci. 2022; 23(4).
PMID: 35216151
PMC: 8877516.
DOI: 10.3390/ijms23042035.
Pan D, Kaufman J, Htut M, Agrawal M, Mazumder A, Cornell R
Cancer Med. 2021; 11(2):358-370.
PMID: 34921527
PMC: 8729045.
DOI: 10.1002/cam4.4451.
The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies.
Chhichholiya Y, Suman P, Singh S, Munshi A
Med Oncol. 2021; 38(8):95.
PMID: 34268641
DOI: 10.1007/s12032-021-01547-1.
StructureMan: A Structure Manipulation Tool to Study Large Scale Biomolecular Interactions.
Xian Y, Xie Y, Silva S, Karki C, Qiu W, Li L
Front Mol Biosci. 2021; 7:627087.
PMID: 33505991
PMC: 7831659.
DOI: 10.3389/fmolb.2020.627087.
Depletion of Survivin suppresses docetaxel-induced apoptosis in HeLa cells by facilitating mitotic slippage.
Han T, Sha H, Ji J, Li Y, Wu D, Lin H
Sci Rep. 2021; 11(1):2283.
PMID: 33504817
PMC: 7840972.
DOI: 10.1038/s41598-021-81563-3.
Tumor-specific lytic path "hyperploid progression mediated death": Resolving side effects through targeting retinoblastoma or p53 mutant.
Hong F, Castro M, Linse K
World J Clin Oncol. 2020; 11(11):854-867.
PMID: 33312882
PMC: 7701912.
DOI: 10.5306/wjco.v11.i11.854.
Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach.
Coutinho M, Santos J, Mendonca L, Matos L, Prata M, Jurado A
Int J Mol Sci. 2020; 21(16).
PMID: 32785133
PMC: 7461213.
DOI: 10.3390/ijms21165732.
Kinesin-5 Eg5 is essential for spindle assembly and chromosome alignment of mouse spermatocytes.
She Z, Zhong N, Yu K, Xiao Y, Wei Y, Lin Y
Cell Div. 2020; 15:6.
PMID: 32165913
PMC: 7060529.
DOI: 10.1186/s13008-020-00063-4.
Rockets, gauges, and pendulums: applying engineering principles to cell biology.
Sullivan W
Mol Biol Cell. 2019; 30(14):1635-1640.
PMID: 31246543
PMC: 6727760.
DOI: 10.1091/mbc.E19-02-0100.
The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity.
Tijhuis A, Johnson S, McClelland S
Mol Cytogenet. 2019; 12:17.
PMID: 31114634
PMC: 6518824.
DOI: 10.1186/s13039-019-0429-1.
Oncogenic Signaling in Tumorigenesis and Applications of siRNA Nanotherapeutics in Breast Cancer.
Kamaruzman N, Aziz N, Poh C, Chowdhury E
Cancers (Basel). 2019; 11(5).
PMID: 31064156
PMC: 6562835.
DOI: 10.3390/cancers11050632.
Cancer drug therapy and stochastic modeling of "nano-motors".
Sherin L, Farwa S, Sohail A, Li Z, Beg O
Int J Nanomedicine. 2018; 13:6429-6440.
PMID: 30410329
PMC: 6198871.
DOI: 10.2147/IJN.S168780.
Universal response in the RKO colon cancer cell line to distinct antimitotic therapies.
Lorz A, Botesteanu D, Levy D
Sci Rep. 2018; 8(1):8979.
PMID: 29895957
PMC: 5997697.
DOI: 10.1038/s41598-018-27267-7.
Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.
Nagaraj A, Kovalenko O, Avelar R, Joseph P, Brown A, Surti A
Clin Cancer Res. 2018; 24(18):4588-4601.
PMID: 29653924
PMC: 6139058.
DOI: 10.1158/1078-0432.CCR-17-2885.
Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells.
Qi C, Wang X, Shen Z, Chen S, Yu H, Williams N
Cell Res. 2018; 28(5):544-555.
PMID: 29497138
PMC: 5951888.
DOI: 10.1038/s41422-018-0018-6.
Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer.
Thompson L, Jeusset L, Lepage C, McManus K
Cancers (Basel). 2017; 9(11).
PMID: 29104272
PMC: 5704169.
DOI: 10.3390/cancers9110151.
Chromosomal instability and acquired drug resistance in multiple myeloma.
Wang W, Zhang Y, Chen R, Tian Z, Zhai Y, Janz S
Oncotarget. 2017; 8(44):78234-78244.
PMID: 29100463
PMC: 5652852.
DOI: 10.18632/oncotarget.20829.